The Food and Drug Administration has approved giving GSK's vaccine for respiratory syncytial virus down to age 50 years old, to those who are at higher risk of severe RSV, the company said Friday ...
The availability of these generics is still unclear as the patent for Entresto does not expire until July 15, 2025. The Food and Drug Administration (FDA) has approved the first generics of ...
FDA approves RSV vaccine The vaccine is approved for at-risk adults in their fifties, making it the first shot approved for the age group. Up Next in wellness What to know about the new vaccine for ...
Geron's CEO said the company anticipates a peak market potential of $1.2 billion in the US and some key EU countries by 2030. In March, by a 12-to-2 margin, the FDA adcomm panel voted in favor of ...
Allowing pharmacists to treat minor illnesses could potentially expand healthcare access to more people and save millions of ...
, opens new tab surged more than 30% on Friday, a day after the company gained its first approval from the U.S. Food and Drug Administration for its blood disorder drug. The health regulator's nod ...
The Food and Drug Administration (FDA) recently approved an expansion of a respiratory syncytial virus (RSV) vaccine for use in at-risk adults over the age of 50. GSK, the vaccine’s maker ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved the first-ever mRNA-1345 vaccine (mRESVIA ...